Inflammatory Bowel Disease: Pathogenesis and Novel Therapeutic Approaches
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 345
Special Issue Editor
Interests: soft tissue and bone tumors; colon cancer; inflammatory bowel disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Inflammatory bowel diseases (IBDs) include Crohn’s disease (CD), ulcerative colitis (UC), coeliac disease, and microscopic colitis, among others. They are chronic immune-mediated conditions, characterized by the recurrent inflammation of the gastrointestinal tract. IBDs affect more than 10 million people worldwide, and different genders are equally affected. It has been shown that patients with IBDs are at an increased risk of colorectal cancer (CRC) and CRC‐related mortality. The intestinal microbiota has been studied as a possible etiology of the disease, but this relationship is not yet clear. Moreover, over the last two decades, biological therapies have revolutionized the treatment of IBDs, although some patients continue to show resistance to medical treatment and require surgical treatment, increasing morbidity. Consequently, more pathological and molecular studies are necessary to improve diagnosis, predicting relapses, prognosis, and therapies in people with IBDs. We are launching this Special Issue with this purpose, hoping that it will be useful for patients, pathologists, and researchers.
Dr. Francisco Giner
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- coeliac disease
- microscopic colitis
- Crohn’s disease
- ulcerative colitis
- microbiota
- biological therapies
- refractory disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
